CTR9 CRISPR/Cas9 KO Plasmid (h): sc-411303
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CTR9 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CTR9 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CTR9 CRISPR/Cas9 KO Plasmid (h) | sc-411303 | 20 µg | $397.00 |
Overview
CTR9 encodes a core component of the PAF1 complex, a conserved transcription elongation factor that associates with RNA polymerase II to coordinate promoter-proximal pause release, productive elongation, and co-transcriptional RNA processing. Through interactions with PAF1C partners, CTR9 influences chromatin modifications linked to active transcription, including histone H2B monoubiquitination and downstream H3 methylation states, thereby shaping gene expression programs. CTR9 activity intersects with pathways controlling cell cycle progression, differentiation, and genome maintenance, and altered PAF1C function has been implicated in transcriptional dysregulation observed in cancer and developmental disorders. As a nuclear regulator of transcriptional output, CTR9 is frequently studied for its role in maintaining transcriptional fidelity and epigenetic states across proliferative and lineage-specific contexts.
CTR9 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CTR9 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CTR9 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CTR9 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CTR9 protein expression.
This CRISPR knockout system enables efficient generation of CTR9-deficient cell models for investigation of CTR9 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CTR9 exon(s) critical for CTR9 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CTR9 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CTR9 CRISPR/Cas9 KO Plasmid (h) and CTR9 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CTR9 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CTR9 HDR Plasmid (h) and CTR9 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CTR9 homology arms to support homology-directed repair at defined CTR9 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.